Patents by Inventor Ganesha RAI
Ganesha RAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240002350Abstract: Disclosed are compounds and methods for preventing or treating necroinflammation associated with ferroptotic processes. The method includes inhibiting 15 lipoxygenase/phosphatidylethanolamine binding protein (15LOX/PEBP1) complex, wherein the inhibitor exhibits a higher binding affinity or binding activity for 15LOX/PEBP1 complex compared to 15LOX alone. Necroinflammation associated with ferroptotic processes causes several pathogenic conditions including upper or lower respiratory disorders, acute or chronic brain injury, renal injury, injury by radiation, neurodegenerative disorder, among others. The disclosed compounds and methods are useful in subjects diagnosed with one or more of these conditions.Type: ApplicationFiled: November 17, 2021Publication date: January 4, 2024Inventors: Sally Ellen MORGANROTH, Valerian KAGAN, Jinming ZHAO, Ganesha RAI, Hulya BAYIR, Yulia TYURINA, Haider DAR, Tamil ANTHONYMUTHU, Joel GREENBERGER, Michael EPPERLY, Diane LUCI, Juan MARUGAN, Anton SIMEONOV, Alexey V. ZAKHAROV, Adam YASGAR, Andrew AMOSCATO
-
Publication number: 20230406859Abstract: Compounds having general formula I or a pharmaceutically acceptable salt, N-oxide, or hydrate thereof are provided herein. Also provided are methods of making the compounds and methods of their use, including in treatment of cancer, autoimmune disorders, and viral infections.Type: ApplicationFiled: June 22, 2021Publication date: December 21, 2023Applicant: The United States of America, as represented by the Secretary, Dept. of Health and Human ServicesInventors: James Inglese, Ganesha Rai Bantukallu, Sandeep Rana, Laurence Lamy
-
Patent number: 10954228Abstract: The disclosure provides a compound of the formula (II) and pharmaceutically acceptable salts thereof. The variables, e.g. n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful for treating cancer and fibrosis. The compounds may be particularly useful for treating forms of cancer in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred. The disclosure also provides pharmaceutical compositions containing a compound of this formula and method for treating patients having cancer, fibrosis, or other conditions in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred.Type: GrantFiled: June 29, 2017Date of Patent: March 23, 2021Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE UAB RESEARCH FOUNDATION, VANDERBILT UNIVERSITY, NATIONAL INSTITUTES OF HEALTH, UNITED STATES DEPT. OF HEALTH AND HUMAN SERVICESInventors: David J. Maloney, Alex Gregory Waterson, Ganesha Rai Bantukallu, Kyle Ryan Brimacombe, Plamen Christov, Chi V. Dang, Victor M. Darley-Usmar, Matthew Hall, Xin Hu, Ajit Jadhav, Somnath Jana, Kwangho Kim, William J. Moore, Bryan T. Mott, Leonard M. Neckers, Anton Simeonov, Gary Allen Sulikowski, Daniel Jason Urban, Shyh Ming Yang
-
Publication number: 20190276448Abstract: The disclosure provides a compound of the formula (II) and pharmaceutically acceptable salts thereof. The variables, e.g. n, R, R3, R10, X, Y, and Z are defined herein. These compounds act as lactate dehydrogenase inhibitors and are useful for treating cancer and fibrosis. The compounds may be particularly useful for treating forms of cancer in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred. The disclosure also provides pharmaceutical compositions containing a compound of this formula and method for treating patients having cancer, fibrosis, or other conditions in which a metabolic switch from oxidative phosphorylation to glycolysis has occurred.Type: ApplicationFiled: June 29, 2017Publication date: September 12, 2019Inventors: David J. MALONEY, Alex Gregory WATERSON, Ganesha Rai BANTUKALLU, Kyle Ryan BRIMACOMBE, Plamen CHRISTOV, Chi V. DANG, Victor M. DARLEY-USMAR, Matthew HALL, Xin HU, Ajit JADHAV, Somnath JANA, Kwangho KIM, William J. MOORE, Bryan T. MOTT, Leonard M. NECKERS, Anton SIMEONOV, Gary Allen SULIKOWSKI, Daniel Jason URBAN, Shyh Ming YANG
-
Patent number: 10287279Abstract: A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.Type: GrantFiled: February 19, 2016Date of Patent: May 14, 2019Assignees: THE CHILDREN'S HOSPITAL CORPORATION, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human ServicesInventors: Klaus Joachin Van Leyen, Theodore R. Holman, David J. Maloney, Ajit Jadhav, Anton Simeonov, Ganesha Rai
-
Publication number: 20160168137Abstract: A systematic screening has revealed a family of compounds that exhibit inhibitory effects on 12/15-lipoxygenase. Accordingly, the present invention relates to the use of these compounds for the inhibition of 12/15-lipoxygenase and for the treatment of a condition involving 12/15-lipoxygenase. Exemplary conditions include, but are not limited to, stroke, periventricular leukomalacia, cardiac arrest with resuscitation, atherosclerosis, Parkinson's disease, Alzheimer's disease, and breast cancer.Type: ApplicationFiled: February 19, 2016Publication date: June 16, 2016Applicants: THE GENERAL HOSPITAL CORPORATION, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SANTA CRUZ, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Klaus VAN LEYEN, Theodore R. HOLMAN, David J. MALONEY, Ajit JADHAV, Anton SIMEONOV, Ganesha RAI
-
Patent number: 8871789Abstract: Disclosed are compounds and pharmaceutical compositions containing compounds that inhibit JMJD2 proteins, including those of the formula (I): wherein R1, R2, R3, R4, and R5 are as defined herein or pharmaceutically acceptable salts thereof. Also disclosed is a method of preventing or treating a viral infection of a host, comprising administering to the host an effective amount of an inhibitor of the JMJD2 family of histone demethylases, for example, a compound of the formula (I). The viral infection may be a primary infection, reactivation of a virus after latency in a host, or may be in a mammal that has undergone, is undergoing, or will undergo immunosuppressive therapy.Type: GrantFiled: January 22, 2013Date of Patent: October 28, 2014Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Thomas Michael Kristie, Yu Liang, Jodi Vogel, David J. Maloney, Ganesha Rai Bantukallu, Anton Simeonov, Ajit Jadhav
-
Publication number: 20130096159Abstract: Disclosed are inhibitors of human 12-lipoxygenase of Formula (I) or (II), wherein R1, R2, R3, and R4 are as defined herein, that are useful in treating or preventing a 12-lipoxygenase mediated disease or disorder, e.g., diabetes. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal.Type: ApplicationFiled: May 18, 2011Publication date: April 18, 2013Applicants: The United States of America, as represented the Secretary Department of Health & Human Service, Thomas Jefferson University, Eastern Virginia Medical School, The Regents of the University of CaliforniaInventors: David J. Maloney, Theodore Holman, Ajit Jadhav, Anton Simeonov, Ganesha Rai Bantukallu, Jerry L. Nadler, Michael Holinstat
-
Publication number: 20110207784Abstract: The invention provides 1,2,5-oxadiazole-containing compounds of Formula (I), wherein R1, A, and R2 are as defined herein, that are useful in treating schistosomiasis. The invention also provides a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, and a method of treating schistosomiasis in a mammal.Type: ApplicationFiled: August 13, 2009Publication date: August 25, 2011Applicants: DEPARTMENT OF HEALTH AND HUMAN SERVICES, ILLINOIS STATE UNIVERSITYInventors: Craig J. Thomas, David J. Maloney, Ganesha Rai Bantukallu, Ahmed A. Sayed, Anton Simeonov, David L. Williams